AMGEN INC — Director's Dealing 2019

Sep 5, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AMGEN INC (AMGN)
CIK: 0000318154
Period of Report: 2019-08-30

Reporting Person: Patton Cynthia M (SVP & CCO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-08-30	Common Stock	M	5749	$156.35	Acquired	32648	Direct
2019-08-30	Common Stock	S	5749	$208.0672	Disposed	26899	Direct
2019-08-30	Common Stock	M	2875	$162.60	Acquired	29774	Direct
2019-08-30	Common Stock	S	2875	$208.0672	Disposed	26899	Direct
2019-08-30	Common Stock	S	4802	$208.0672	Disposed	22097	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-08-30	Nqso (Right to Buy)	$156.35	M	5749	Disposed	2026-05-03	Common Stock (5749)	Direct
2019-08-30	Nqso (Right to Buy)	$162.60	M	2875	Disposed	2027-05-01	Common Stock (2875)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	264.49	Indirect

Footnotes

F1: The price reported is an average price. The prices ranged from $207.425 to $208.520 per share for this cashless exercise of 5,749 stock options expiring May 3, 2026. Full information regarding the number of shares sold at each separate price within the range set forth above is available upon request by the SEC staff, the issuer or a security holder of the issuer.

F2: The price reported is an average price. The prices ranged from $207.425 to $208.520 per share for this cashless exercise of 2,875 stock options expiring May 1, 2027. Full information regarding the number of shares sold at each separate price within the range set forth above is available upon request by the SEC staff, the issuer or a security holder of the issuer.

F3: The price reported is an average price. The prices ranged from $207.425 to $208.520 per share. Full information regarding the number of shares sold at each separate price within the range set forth above is available upon request by the SEC staff, the issuer or a security holder of the issuer.

F4: These shares include the following RSUs granted under the Company's equity plans: 348 RSUs which vest on 5/3/2020; 660 RSUs which vest in installments of 325 on 5/1/2020 and 335 on 5/1/2021; 901 RSUs which vest in installments of 297 on 4/27/2020, 297 on 4/27/2021 and 307 on 4/27/2022; and 902 RSUs which will vest in installments of 297 on 5/3/2021, 298 on 5/3/2022 and 307 on 5/3/2023. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F5: These shares include 116 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

F6: These are shares acquired under the Company's 401(k) Plan and represent interests in the Company's stock fund as of this filing.